- Poster presentation
- Open Access
Interim results of the SHARF4 study: outcome of acute renal failure with different treatment modalities
© BioMed Central Ltd. 2004
- Published: 15 March 2004
- Acute Renal Failure
- Renal Replacement Therapy
- Continuous Renal Replacement Therapy
- Interim Result
- Sofa Score
It is important for ICU physicians to predict the mortality of acute renal failure (ARF) in the first 24–48 hours. For this the SHARF II score at 0 and 48 hours has been developed . This study will look at short-term and long-term morbidity and mortality with different modes of treatment in ARF.
A prospective multicentre randomised clinical trial. The target population was 1600 consecutive adult patients with ARF. Patients needing renal replacement therapy (RRT) were randomised to either slow extended daily dialysis (SLEDD) or continuous venovenous hemofiltration (CVVH). Randomisation was done according to the SHARF II0 score (< 30, 30–60 and > 60). Interim study endpoints were hospital morbidity and mortality.
The interim results of an ongoing study show that the SHARF score, with parameters at 0 and 48 hours, has good predictive value in estimating prognosis in ARF patients. Overall mortality was 56.5%, and 59% needed RRT. Mortality was the same regardless of RRT used. Major problems lay in recruiting centers using both techniques equally. The randomisation rate is lower than expected.